

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jiangxi Institute of Biological Products Inc.

江西生物製品研究所股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6915)

**VOLUNTARY ANNOUNCEMENT
OBTAINING THE APPROVAL CERTIFICATE FOR
VETERINARY TETANUS ANTITOXIN**

This announcement is made by Jiangxi Institute of Biological Products Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors (the “**Directors**”) of the Company (the “**Board**”) is pleased to announce that Chifeng Bo-en Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the Company, has recently obtained the Approval Certificate of Veterinary Drug Product (the “**Approval Certificate**”) for our veterinary tetanus antitoxin product.

Our veterinary tetanus antitoxin is primarily used for the prevention and treatment of tetanus infections in animals, providing passive immune protection for animals at risk of tetanus infection by neutralizing the tetanus toxin.

The Board considers that the attainment of the Approval Certificate has further enriched the Group’s product portfolio, laid the foundation for the Group’s continued expansion into the animal health market, and is expected to further enhance the Group’s overall competitiveness and long-term development potential.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Jiangxi Institute of Biological Products Inc.
江西生物製品研究所股份有限公司
Ms. Jing Yue
Chairperson and Executive Director

Hong Kong, July 3, 2026

As of the date of this announcement, the Board comprises: (i) Ms. JING Yue, Mr. YAO Xiaodong, Mr. LI Changqing and Ms. JING Ruihua as executive Directors; (ii) Ms. YU Ailian and Mr. XIAO Changqing as non-executive Directors; and (iii) Dr. ZOU Pingxue, Dr. TSANG Hiu Leong and Mr. WU Di as independent non-executive Directors.